Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification

NCT07417501 · tracked via the Priya Life Science China tracker

Sponsor

Tongji Hospital

Phase

Phase 2

Started

2026-05-07

Last updated

2026-10-14

Condition(s) studied

Solid Tumors

Investigational drug(s) / intervention(s)

Lenvatinib plus PD-1 Inhibitor →

Lenvatinib plus PD-1 Inhibitor: This is a combination therapy. Lenvatinib is administered orally once daily at a weight-based dose (12 mg for patients ≥60 kg; 8 mg for patients \<60 kg). The PD-1 inhibitor component is not fixed; specific agents (such as pembrolizumab, sintilimab, etc.) may be used according to institutional standards and drug availability. The PD-1 inhibitor is administered intravenously at a dose of 200 mg every 3 weeks. Treatment continues until disease progression, unacceptable toxicity, or other protocol-specified criteria for discontinuation are met.

Study summary

The goal of this clinical trial is to learn if the combination of lenvatinib and a PD-1 inhibitor (a type of immunotherapy) works to treat advanced solid tumors that have a specific genetic change called "11q13 amplification". It will also learn about the safety of this combination. The main questions it aims to answer are:

How many participants' tumors shrink or stop growing after receiving the combination therapy? What side effects do participants have when taking this combination therapy? All participants in this study will receive the same drug combination. Researchers will look at the results to see how well the treatment works.

Participants will:

Take lenvatinib orally once daily and receive PD-1 inhibitor by intravenous infusion every 3 weeks.

Visit the clinic regularly for checkups, blood tests, and CT or MRI scans to see how the tumor is responding.

Be followed for side effects and survival over time.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Voluntary signing of the informed consent form, age ≥ 18 years at the time of signing, any gender. * Histologically or cytologically confirmed unresectable locally advanced or metastatic solid malignant tumor, including but not limited to: esophageal carcinoma, head and neck squamous cell carcinoma, breast cancer, lung cancer, hepatobiliary malignancies, and other solid tumors deemed eligible by the investigator. * Confirmed tumor presence of chromosome 11q13 amplification (amplification of at least one gene among CCND1, FGF3, FGF4, FGF19) via NGS testing. * No prior treatment with lenvatinib. * ECOG Performance Status of 0 or 1, with an estimated life expectancy ≥ 3 months. * At least one radiologically measurable lesion as defined by RECIST 1.1 criteria (tumor lesion with longest diameter ≥10 mm on CT scan, or lymph node with short axis ≥15 mm). * Adequate organ function. Exclusion Criteria: * Presence of active or previously documented autoimmune or inflammatory disorders. * Known hypersensitivity to any component of the study drugs (lenvatinib or PD-1 inhibitors). * Significant bleeding tendency or coagulation dysfunction, or occurrence of major bleeding within 4 weeks prior to enrollment. * Uncontrolled hypertension (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg) despite medication. * Received chemotherapy, radiotherapy, major surgery, or other anticancer therapy within 4 weeks prior to enrollment. * Pregnant or lactating women, or patients of childbearing potential unwilling to use effective contraception. * Inability to comply with the study protocol for treatment or scheduled follow-up assessments.

Primary outcome measure(s)

Objective Response Rate (ORR) — From first dose of study treatment until the first documented disease progression or start of new anticancer therapy, whichever occurs first, assessed up to approximately 24 months.
Proportion of participants achieving a best overall response of Complete Response (CR) or Partial Response (PR) according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). Tumor response will be assessed by investigators via contrast-enhanced CT or MRI scans.

Trial sites (2)

Facility	City	Region	Status
Tongji Hospital	Wuhan	Hubei	Not Yet Recruiting
Tongji Hospital	Wuhan	Hubei	Recruiting

More Tongji Hospital trials in China

SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer Starting soon

Safety, Tolerability, and Preliminary Efficacy of KD01 Via Intravesical Instillation in Bladder Cancer (BC) Recruiting

Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC Recruiting

AI-Guided Surveillance and Curative Salvage of Recurrence After Hepatocellular Carcinoma Resection or Ablation Starting soon

Clinical Evaluation of New Biomarkers for Ischemic Cerebrovascular Disease Recruiting

Other trials for the same condition

A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Solid Tumors Recruiting

IL-15 Enhanced NK Cell Therapy for Solid Tumors Recruiting

A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors Recruiting

A Phase 2 Clinical Study of ABSK061 and ABSK043 Recruiting

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07417501 on ClinicalTrials.gov ↗ ← All trials in China